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Structure modifying drugAbstract Aim of the work: The aim of this study was to detect and compare the efﬁcacy of topical
and oral glucosamine/chondroitin sulfate on knee OA (OAK), and to prove their efﬁcacy on spar-
ing the articular cartilage among the Egyptian patients.
Patients and methods: 180 patients with OAK were included and randomly divided into
2 groups, each of 90 patients. One group took 1500 mg oral glucosamine/chondroitin sulfate and
the other group used topical glucosamine/chondroitin sulfate for 3 months. The diagnosis was based
on the American College of Rheumatology (ACR) criteria for OAK. Age, duration of OA, and
body mass index (BMI) of the patients were recorded. Knee radiographs were assessed with the
Kellgren–Lawrence scale. The severity of knee pain, stiffness, and disability were measured using
the visual analog scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC). The serum C-reactive protein (CRP) and Cartilage oligomeric matrix protein
changes (COMP) were measured.
Results: No statistical difference was found between the 2 groups regarding age, sex, duration of
OA, and Kellgren–Lawrence grading scale. Both VAS and WOMAC subscores showed signiﬁcant
equal relief ofpainand joint functionbetween the2groups regardless of the severityordurationofknee
OA. Topical glucosamine was superior to the oral route in improving stiffness and function.
Conclusion: Topical and oral glucosamine/chondroitin sulfate are safe and equally effective
on improving knee pain, stiffness and function. Glucosamine/chondroitin sulfate is beneﬁcial as a
symptomatic treatment and not as a cartilage sparing drug in the treatment of OAK.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Osteoarthritis (OA) is the most common musculoskeletal prob-
lem in individuals above 50 years of age. It is a progressive dis-
ease that can worsen physical function over time. Worldwide
86 Y.H. Hammad et al.estimates indicate that 9.6% of men and 18% of women
P60 years have symptomatic OA. In 1990, OA was estimated
to be the eighth leading non-fatal burden of disease, account-
ing for 2.8% of total individuals living with disability [1]. OA
can affect the quality of life; mainly walking and climbing
stairs [2]. Osteoarthritis has a signiﬁcant negative impact on
the economy, with its total cost estimated as equivalent of
1% of the gross national product (GNP) per year in the UK
[2]. Over a 1-year period in the UK, there were 114,500 hospi-
tal admissions, in 2000, there were over 35,000 knee replace-
ments performed at a cost of £405 million and also, 36
million working days were lost due to OA alone, at an esti-
mated cost of £3.2 billion in lost production. At the same time
£215 million was spent on social services for OA [3].
OA is often associated with the knee, hip, spine, and ﬁngers
[4,5]. It involves all tissues of the diarthrodial joints including
the bone, cartilage and supporting elements. OA is character-
ized by focal degeneration of joint cartilage and formation of
new bone in the form of osteophytes at the base of the cartilage
lesion in the subchondral bone and at the joint margins [6].
Our joints are cushioned by cartilages and lubricated with
synovial ﬂuid such that we can move and twist any joint freely
without pain. The principal lubricating substances in our car-
tilage, tendons, ligaments, synovial ﬂuid and mucous mem-
branes are proteoglycans and glycosaminoglycans (GAGs).
Glucosamine which is naturally produced by the body is the
main ingredient needed to produce GAGs. Glucosamine stim-
ulates the chondrocytes to produce proteoglycans and increase
the production of hyaluronic acid resupply of synovial ﬂuid to
act as a lubricant, while chondroitin sulfate attracts water into
the cartilage and acts as a shock absorber. The proteoglycans
are subjected to continuous metabolic turnover, undergoing
constant breakdown and resynthesis. The imbalances in these
processes that occur with aging or with other medical condi-
tions are partially responsible for the development of arthritis.
In old men, the body loses the capacity to produce sufﬁcient
glucosamine causing thinning of the cartilage and leads to joint
degeneration [7].
In OA, the rate of synthesis and secretion of matrix-degrad-
ing metalloproteinases by the chondrocyte are greatly
increased leading to a loss of the proteoglycans from the extra-
cellular matrix. Also, lysosomal enzymes can cleave both hyal-
uronic acid and chondroitin 6-sulfate. It is to be noted that
proteoglycan and collagen synthesis continue to rise in propor-
tion to the severity of the lesion [8]. It is tempting to believe
that ingestion of these agents would somehow provide beneﬁ-
cial help to the cartilage [9].
An important biomarker of cartilage degradation is termed
cartilage oligomeric matrix protein (COMP). The serum levels
were found to reﬂect the extent of cartilage matrix turnover in
patients with OA [7,10–12]. COMP is a pentameric glycopro-
tein which is highly expressed in the cartilage. It binds colla-
gens I, II and IX accordingly, this abundant cartilage matrix
protein might have several roles in cartilage tissue homeostasis,
including regulation of collagen ﬁbril formation and mainte-
nance of the integrity and properties of collagen network
[13]. The rate of synthesis of COMP is enhanced in the human
cartilage with early OA lesions and rising levels of COMP have
been found to correlate with progression of the disease [14].
COMP was initially thought to be cartilage speciﬁc, over the
past few years it has been identiﬁed in all structures of the
joint, including ligaments, meniscus, tendons, and synovium.Serum level of COMP was found also to be increased after
physiological cyclic loading [15].
Previous studies have demonstrated an association between
OA progression and inﬂammation as measured by systemic C-
reactive protein (CRP) levels. The more aggressive disease seen
in OA patients with elevated CRP levels may be linked to a
more inﬂammatory synovial response in the diseased joint [16].
For decades, the traditional pharmacologic management of
OA has been mainly symptomatic without well-documented
inﬂuence on the duration of the disease and its progression.
Dietary supplements have become mainstream products in
the management of OA like glucosamine sulfate [17]. Glucosa-
mine sulfate, the pharmaceutical derivative of the naturally
occurring aminomonosaccharide glucosamine, a constituent
of glycosaminoglycan in the cartilage matrix and synovial
ﬂuid, has been used orally for the treatment of OA since the
early 1980s. After oral administration, glucosamine sulfate is
bioavailable and reaches the articular cartilage. It is preferen-
tially incorporated by the chondrocytes into the components of
the glycosaminoglycan chains in the intact cartilage, stimulates
the synthesis of physiological proteoglycans, and decreases the
activity of catabolic enzymes, including metalloproteases [18].
In addition, the compound may reverse some of the nega-
tive effects of interleukin-1 on cartilage metabolism [19]. Also,
there is a mild anti-inﬂammatory effect exerted by the suppres-
sion of superoxide radical generation or the inhibition of
inducible nitric oxide synthesis and selectively, of the cycloox-
ygenase-2 pathway.
Contradictory researches were published regarding the efﬁ-
cacy of glucosamine and chondroitin sulfate in OA. Some
researchers found that glucosamine has no value in the man-
agement of OA [20,21]. Others found that oral glucosamine
and chondroitin sulfate may relieve the pain and joint stiffness,
physical function, overall questionnaire score, and analgesic
use associated with OA [22]. Moreover; they may act as a dis-
ease-modifying agent in patients with mild to moderate OA
showing delayed radiographic progression of OA of the knee
[23–28]. Most currently available glucosamine-based drugs
and supplements are taken orally at a dosage (1500 mg daily).
The dose reaching the articular cartilage is a fraction of a per-
centage of the oral dose (10–20%) [29]. Lately; an emulsion
matrix [obalin] was available. It can hold up to 20% glucosa-
mine compounds in a stable emulsion which can deliver gluco-
samine transdermally to the joints [19]. Chondroitin sulfate
acts as a carrier substance to enhance dermal penetration
[30]. Unfortunately, no data are available comparing the efﬁ-
cacy of the two products in managing OA of the knee [31].
The aim of this study was to detect, compare the efﬁcacy of
topical and oral glucosamine/chondroitin sulfate on knee OA
and to prove their efﬁcacy on sparing the articular cartilage
among the Egyptian patients.2. Patients and methods
One hundred eighty outpatient females aged 32 to 62 years,
diagnosed as OA of the knee based on the criteria of the Amer-
ican College of Rheumatology [31] were included. The follow-
ing predetermined exclusion criteria were considered on
enrollment: Pregnant females; other rheumatologic disorders
causing erosive arthritis of the knee; cases with severe osteoar-
thritis or with moderate or marked knee effusion; regular
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of oral or topical glucosamine in the previous 6 weeks; use of
intra-articular injection of steroids or hyaluronic acid during
the previous 6 months. Diabetic patients were informed that
glucosamine sulfate causes an increase in blood glucose level
and that blood glucose level should be monitored [29].
2.1. Study design
A follow up study was conducted according to a randomized
design in the department of Rehabilitation and Rheumatology,
Alexandria University Hospitals-Alexandria-Egypt, between
December 2007 and November 2011. The protocol was
approved by the college of Medicine, Alexandria review board,
and patients provided written informed consent. Patients were
screened at a baseline visit that included a physical examina-
tion, knee examination, knee radiographs, and symptom ques-
tionnaire and serum samples were taken for the biochemical
analysis of human cartilage oligomeric matrix protein (COMP)
and C reactive protein (CRP) before and after the treatment
period.
2.2. Biochemical methods
1- Estimation of human COMP by ELISA [32]: [Wielisa
COMP assay] IDEON Research Park S-223 70 Lund
Sweden. The assay utilizes native human articular carti-
lage COMP coated to well microtitre plates, and a rabbit
polycolonal antiserum directed to human COMP. An
overnight preincubation step of sample with primary
antiserum, after which the solution is transferred to
the COMP coated plate. Bound antibodies are detected
after wash using alkaline phosphatase labeled antirabbit
IgG conjugate.
2- Estimation of CRP by the turbidimetric method [33]. It
assesses agglutination of latex particles coated with anti-
body against CRP by quantifying the absorbed light.
2.3. Treatment protocol
After enrollment in the study, the patients were randomly
divided into 2 groups of ninety patients each. The ﬁrst group
used topical glucosamine chondroitin sulfate preparation and
the second group took 1500 mg of oral glucosamine chondroi-
tin sulfate daily. The 2 groups were followed up until comple-
tion of the 3 month treatment course. At the end of the
treatment period, a second clinic visit was made and included
the same previous examination and laboratory investigations.
Acetaminophen [500 mg/tablet] was allowed when needed,
while no other treatment for osteoarthritis was allowed during
the study period [25]. Patients under physiotherapy (infrared
and/or TENS) program were allowed to continue their sched-
uled program.
2.4. Assessment of the knee joints
Clinical and radiological examinations of the knee joint were
done for each patient before and after the treatment period.
Weight-bearing anteroposterior and lateral semiﬂexedradiographs were recorded for both knees in each patient.
They were radiologically graded according to the Kellgren–
Lawrence [34]. All the ﬁlms were assessed by a specialized
reader.
2.5. Assessment of symptom change
Symptoms of knee osteoarthritis were evaluated at the ﬁrst
visit and at the end of the treatment period by using the Visual
analog scale (VAS) [35] and Western Ontario and McMaster
Universities (WOMAC) osteoarthritis index [6].
Statistical analysis: Study data were statistically analyzed
using the Statistical Package for Social version program (SPSS
program-version 18). Data were expressed as mean ± stan-
dard deviation (SD) or proportions (%). Statistical analysis
was carried out using the paired t-test, Wilcoxon Signed Ranks
Test, proportion hypothesis test and Mann–Whitney test
(P 6 0.05 was considered as statistically signiﬁcant).
3. Results
All the included OA patients had completed the 3 month treat-
ment duration. Table 1 gives the baseline characteristics of the
2 groups. No signiﬁcant differences were found between the 2
groups as regards the age, body mass index (BMI) and dura-
tion of knee OA.
Clinical assessment proved that all the included patients
were suffering from knee pain. The mean duration of knee
pain was 32.8 ± 27.8 and 35.4 ± 20.9 months (among the
local and oral groups respectively). The mean visual analog
scale for pain assessment was 48.8 ± 4.3% and
62.2 ± 10.1% of the local and oral groups of patients respec-
tively. Also, the mean pain severity score was less than 14
points on the WOMAC index subscale among the 2 groups
of patients. The mean stiffness and knee joint function using
WOMAC subscales were less than 5 and 23 points respectively
among the 2 groups. On radiological assessment, the score of
severity among the included patients ranged between 2 and 3
Kellgren and Lawrence grading.
3.1. Knee pain change after glucosamine/chondroitin sulfate
treatment
Pain and stiffness decreased markedly in both treatment
groups after the 3 month treatment duration with glucosamine
sulfate according to the VAS (P= 0.000) for the local and oral
groups respectively, and according to the WOMAC index
score points (P= 0.000) for the local and oral groups
(Table 2).
3.2. Stiffness and function changes
Joint stiffness decreased markedly in both treatment groups
according to the WOMAC index score points (P= 0.000)
and also regarding joint function (P= 0.001) (Table 2).
Improvement of pain, stiffness and joint function in knee
osteoarthritis patients of local and oral groups, after treatment
is presented in Table 3.
All patients were complaining of pain and joint stiffness
prior to the study. According to VAS, pain was decreased by
Table 4 Radiological assessment of the knee osteoarthritis
patient treated groups according to Kellgren-Lawrence grade
(before and after treatment).
Knee OA patients (n= 90 in each group)
N (%) Kellgren–Lawrence grade
Grade 2 Grade 3
Local group
Before 81 (90) 9 (10)
After 81 (90) 9 (10)
Oral group
Before 76 (84) 14 (16)
After 76 (84) 14 (16)
OA: osteoarthritis.
Table 1 Baseline demographic and clinical characteristics of
the knee osteoarthritis patients according to the treatment
received (Local and Oral).
Characteristic Knee OA patients according
to treatment
mean ± SD Local (n= 90) Oral (n= 90)
Age (years) 48.6 ± 8.2 50 ± 6.2
Duration of knee pain (months) 32.8 ± 27.8 35.4 ± 20.9
BMI (kg/m2) 28.3 ± 2.3 29.9 ± 2.3
VAS (%) 48.8 ± 14.3 62.2 ± 10.1
WOMAC index score
Pain 13.2 ± 4.96 13.4 ± 2.5
Stiﬀness 4.8 ± 1.9 4.5 ± 1.7
Function 22.5 ± 6.6 23 ± 4.8
OA: osteoarthritis, BMI: body mass index, VAS: visual analog
scale, WOMAC: Western Ontario and McMaster Universities
(WOMAC) osteoarthritis index.
88 Y.H. Hammad et al.about 50% in 36% of the treated patients. No improvement
was detected among 25% of the orally treated group compared
to 16% of the locally treated patients. Decrease of joint stiff-
ness by more than 50% was recorded in 66% of the patients
of the locally treated group compared to 46% of the oral
group. 25% decrease in joint stiffness was present among
33% of the patients. Regarding joint function; signiﬁcant
improvement was found among the 2 groups. Improvement
(>50%) was recorded among 54% of the local group com-Table 2 Clinical characteristics of patients with knee osteoarthritis
Characteristic Knee OA patients according to treatment grou
Mean ± SD Local (n= 90)
Before After P
VAS (%) 48.8 ± 14.3 32.5 ± 21.4 0
WOMAC score
Pain 13.2 ± 4.96 7.5 ± 3.5 0
Stiﬀness 4.8 ± 1.9 2.3 ± 1.4 0
Function 22.5 ± 6.6 11.9 ± 7.1 0
Table 3 Improvement of pain, stiffness and joint function in knee
Improvement N (%) Knee OA patients (n= 90 in ea
P75% 50
Local group
Pain 7 (8) 33
Stiﬀness 0 (0) 59
Function 0 (0) 49
Oral group
Pain 7 (8) 33
Stiﬀness 0 (0) 42
Function 0 (0) 32
OA: osteoarthritis.pared to 35% of the oral group patients. Nearly, no improve-
ment was found in about 40% of the treated patients. The
degree of improvement of the joint function to treatment
was negatively correlated with the duration of knee pain.
Radiological assessment of the treated groups: Ninety per-
cent of the included patients of the local treated group were
classiﬁed as grade 2, while 10% were classiﬁed as grade 3 Kell-
gren and Lawrence severity score. Radiological reassessment
at the end of the study revealed no change of radiological
severity for all the patients and among the two groups




.000 62.2 ± 10.1 39.6 ± 18.8 0.000
.000 13.4 ± 2.5 8.3 ± 2.4 0.000
.000 4.5 ± 1.7 2.7 ± 0.7 0.000
.000 23 ± 4.8 15.4 ± 3.4 0.000
osteoarthritis patients of local and oral groups, after treatment.
ch group)
–75% 25–50% <25%
(37) 36 (40) 14 (15)
(66) 30 (33) 1 (1)
(54) 5 (6) 36 (40)
(37) 27 (30) 23 (25)
(46) 30 (34) 18 (20)
(35) 22 (25) 36 (40)
Table 5 Biochemical characteristics of patients with knee osteoarthritis before and after local and oral treatment.
Biochemical Characteristic Knee OA patients in treatment group (n= 90 each)
Local P Sig Oral P Sig
CRP (mg/L)
Before 5.7 ± 7.1 0.16 NS 4.7 ± 2.2 0.13 NS
After 5.6 ± 6.8 4.4 ± 1.96
COMP (lg/ml)
Before 37.4 ± 7.4 0.11 NS 67.9 ± 24.9 0.68 NS
After 37.3 ± 7.3 67.6 ± 24.8
OA: osteoarthritis, CRP: C-reactive protein, COMP: cartilage oligomeric matrix protein.
Table 6 Knee osteoarthritis patients need analgesia (acetami-
nophen) and physiotherapy before and after local and oral
treatment.
N (%) Knee OA patients (n= 90 in each group)
Acetaminophen Physiotherapy P
Local group
Before 72 (80) 36 (40) 0.000
After 20 (18) 9 (10) 0.000
Oral group
Before 81 (90) 45 (50) 0.000
After 30 (27) 6 (16) 0.000
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patient sera before and after treatment where, no signiﬁcant
changes were found among the 2 groups (Table 5).
Cartilage oligomeric matrix protein (COMP) changes: The
COMP was measured in the sera of both groups before and
after the 3 month treatment duration. No signiﬁcant changes
were detected among the 2 groups after treatment (Table 5).
From Table 2 on comparing the results of oral treatment
versus local treatment, it is evident that both are equal as
regards symptomatic improvement of pain, joint stiffness
and joint function. Meanwhile, there was no signiﬁcant change
in levels of the human COMP and C-RP after treatment
(Table 5).
There was no statistical difference between the two treated
groups regarding the patient need of physiotherapy (infrared
and/or TENS) and analgesic tablets (acetaminophen) either
before or after the study period (Table 6).
4. Discussion
OA of the knee joint is a disorder characterized by a multiplex
of symptoms. This study was designed to detect the effect of
glucosamine/chondroitin sulfate on knee OA, their efﬁcacy
to stop or improve the degradation of the articular cartilage
and to compare the efﬁcacy of the topical versus the oral prep-
arations among the Egyptian patients. The included patients
were randomly divided into 2 groups, each of 90 patients.
One group took oral and the 2nd group took topical glucosa-
mine/chondroitin sulfate preparations for 3 months. The 2
groups were of matched age, sex, BMI and duration of knee
pain. Knee examination, radiological assessment and biologi-
cal investigations were carried out for all the patients beforeand after treatment. Joint pain and stiffness were the main
symptoms in this study, where VAS ranged between 30 and
85%. Also, WOMAC pain subscale ranged between 7 and 20
points. Knee stiffness measured by WOMAC subscale ranged
between 1 and 5 points. Daily activity and knee joint function
were affected in most of the patients where WOMAC subscale
for joint function ranged between 13 and 31 points. Moreover,
all the included patients were suffering from knee cartilage
degradation on radiological assessment, ranged between 2
and 3 Kellgren and Lawrence severity scale. No changes in
the severity score and joint space width were noticed after
completion of the treatment duration. In this study, all the
patients completed the treatment duration which reﬂects the
safety of the compound.
The study revealed that the two groups of patients showed
marked relief of pain after treatment with a subsequent signif-
icant decrease of the need for analgesic tablets and physiother-
apy. There was no signiﬁcant difference between the 2 groups
regarding pain relief after treatment. The percentage of
patients showed that pain improvement is comparable with
other studies [19].
Joint painmeasured byVASwas improved in all the included
patients. However, there was no signiﬁcant difference found
between the locally and orally treated patients. Decrease of joint
stiffness was better in the locally treated group. Rubbing of the
joint during application of the glucosamine cream may have an
additional value in relieving the joint stiffness. Regarding joint
function, signiﬁcant improvement after treatment was found
among the 2 groups. However, better response was recorded
among the locally treated patients. The degree of response of
the joint function to treatment was negatively correlated with
the duration of knee pain (bad response to the drugwas recorded
in OA patients with more than 24 month duration).
4.1. Joint cartilage turnover
1- The CRP is recognized as one of the most sensitive mea-
sures of inﬂammation. It is highly associated with OAK.
However, its high correlation with obesity limits its util-
ity as an exclusive marker for OAK [36]. In this study,
there was a statistically insigniﬁcant decrease of the
mean CRP after treatment among the 2 groups.
2- The COMP is considered as a marker of joint cartilage
turnover. Its level increases in the synovial ﬂuid of
patients suffering from OA [37]. In this study, there
was no signiﬁcant difference of the mean serum COMP
level after treatment among the 2 groups.
90 Y.H. Hammad et al.In conclusion, this study showed that glucosamine sulfate is
effective as pain, stiffness and function improving drug. The
local application is slightly more effective than the oral route
of administration with nearly no side effects during the 3 month
duration of treatment. This study revealed that glucosamine sul-
fate is beneﬁcial as symptomatic relief of pain, stiffness and
improving the joint function rather than a cartilage restoring
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